Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results-Reference-Cited by-同舟云学术

Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results

Published:2017-07-17 Issue:4 Volume:121 Page:279-289
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Kuna Piotr¹,Aurivillius Magnus²,Jorup Carin²,Prothon Susanne³,Taib Ziad³,Edsbäcker Staffan⁴

Affiliation:

1. Department of Internal Medicine, Asthma and Allergy; Barlicki University Hospital; Medical University of Lodz; Lodz Poland

2. AstraZeneca Global Medicines Development; Gothenburg Sweden

3. AstraZeneca Early Clinical Development; Gothenburg Sweden

4. Department of Clinical and Experimental Pharmacology; Laboratory Medicines Unit; Lund University; Lund Sweden

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcpt.12768/fullpdf

Reference44 articles.

1. GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) http://goldcopd.org/

2. TORCH investigators: salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease;Calverley;N Engl J Med,2007

3. Withdrawal of inhaled glucocorticoids and exacerbations of COPD;Magnussen;N Engl J Med,2014

4. Inhaled corticosteroids for stable obstructive pulmonary disease;Yang;The Cochrane Library,2012

5. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis;Kew;Cochrane Database Syst Rev,2014

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Glucocorticoid Receptor: Isoforms, Functions, and Contribution to Glucocorticoid Sensitivity;Endocrine Reviews;2024-03-29

2. Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?;Endocrine Reviews;2023-05-30

3. The long winding road to the safer glucocorticoid receptor (GR) targeting therapies;Oncotarget;2022-02-18

4. Improving the risk-to-benefit ratio of inhaled corticosteroids through delivery and dose: current progress and future directions;Expert Opinion on Drug Safety;2021-11-26

5. Research Advances in COPD Drugs and Novel Targets;Nano LIFE;2021-09